Is cancer vaccination feasible at older age?

Experimental Gerontology

Volumn 54, Issue , 2014, Pages 138-144

  Gravekamp, Claudia ^a   Jahangir, Arthee ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Adaptive immune system; Aging; Cancer immunotherapy; Cancer vaccines; Immune system; Innate immune system

Indexed keywords

CANCER VACCINE; TUMOR ANTIGEN;

ADAPTIVE IMMUNITY; AGING; ANTIGEN ANTIBODY REACTION; ANTIGEN PRESENTING CELL; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CELLULAR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; DRUG SAFETY; FEASIBILITY STUDY; HUMAN; IMMUNE DEFICIENCY; IMMUNOPATHOLOGY; IMMUNOSTIMULATION; INNATE IMMUNITY; MALIGNANT NEOPLASTIC DISEASE; METASTASIS POTENTIAL; MORBIDITY; NATURAL KILLER T CELL; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE ACTIVATION; TUMOR MICROENVIRONMENT; FORECASTING; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASMS; PROCEDURES; T LYMPHOCYTE;

ADAPTIVE IMMUNITY; ANTIGEN-PRESENTING CELLS; CANCER VACCINES; FEASIBILITY STUDIES; FORECASTING; HUMANS; IMMUNITY, INNATE; IMMUNOTHERAPY; NEOPLASMS; T-LYMPHOCYTES;

EID: 84898842511     PISSN: 05315565     EISSN: 18736815     Source Type: Journal    
DOI: 10.1016/j.exger.2014.01.025     Document Type: Review

References (82)

1. Agrawal A., Gupta S. Impact of aging on dendritic cell functions in humans. Ageing Res. Rev. 2011, 10:336-345. 10.1016/j.arr.2010.06.004.
2. Agrawal A., et al. Altered innate immune functioning of dendritic cells in elderly humans: a role of phosphoinositide 3-kinase-signaling pathway. J. Immunol. 2007, 178:6912-6922.
3. Biron C.A., Brossay L. NK cells and NKT cells in innate defense against viral infections. Curr. Opin. Immunol. 2001, 13:458-464.
4. Bluestone J.A., Abbas A.K. Natural versus adaptive regulatory T cells. Nat. Rev. Immunol. 2003, 3:253-257. 10.1038/nri1032.
5. Butts C., et al. Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. J. Clin. Oncol. 2005, 23:6674-6681. 10.1200/JCO.2005.13.011.
6. Castro F., et al. Vaccination with Mage-b DNA induces CD8 T-cell responses at young but not old age in mice with metastatic breast cancer. Br. J. Cancer 2009, 101:1329-1337. 10.1038/sj.bjc.6605329.
7. Chandra D., Jahangir A., Quispe-Tintaya W., Einstein M.H., Gravekamp C. Myeloid-derived suppressor cells have a central role in attenuated Listeria monocytogenes-based immunotherapy against metastatic breast cancer in young and old mice. Br. J. Cancer 2013, 108:2281-2290. 10.1038/bjc.2013.206.
8. + regulatory T cells via FasL protein transfer enhances the therapeutic efficacy of adoptive T cell transfer. Cancer Res. 2007, 67:1291-1298. 10.1158/0008-5472.CAN-06-2622.
9. Della Bella S., et al. Peripheral blood dendritic cells and monocytes are differently regulated in the elderly. Clin. Immunol. 2007, 122:220-228. 10.1016/j.clim.2006.09.012.
10. Dunston C.R., Griffiths H.R. The effect of ageing on macrophage Toll-like receptor-mediated responses in the fight against pathogens. Clin. Exp. Immunol. 2010, 161:407-416. 10.1111/j.1365-2249.2010.04213.x.
11. Effros R.B. Replicative senescence of CD8 T cells: effect on human ageing. Exp. Gerontol. 2004, 39:517-524. 10.1016/j.exger.2003.09.024.
12. Effros R.B. Role of T lymphocyte replicative senescence in vaccine efficacy. Vaccine 2007, 25:599-604. 10.1016/j.vaccine.2006.08.032.
13. Emoto M., Kaufmann S.H. Liver NKT cells: an account of heterogeneity. Trends Immunol. 2003, 24:364-369.
14. - T cells and inhibit both T-cell proliferation and CTL function. Hum. Immunol. 2004, 65:142-156. 10.1016/j.humimm.2003.12.001.
15. Gabrilovich D.I., Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 2009, 9:162-174. 10.1038/nri2506.
16. Gajewski T.F., Meng Y., Harlin H. Immune suppression in the tumor microenvironment. J. Immunother. 2006, 29:233-240. 10.1097/01.cji.0000199193.29048.56.
17. Giaccone G., et al. A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors. Clin. Cancer Res. 2002, 8:3702-3709.
18. Goldman B., DeFrancesco L. The cancer vaccine roller coaster. Nat. Biotechnol. 2009, 27:129-139. 10.1038/nbt0209-129.
19. Gomez C.R., Nomellini V., Faunce D.E., Kovacs E.J. Innate immunity and aging. Exp. Gerontol. 2008, 43:718-728. 10.1016/j.exger.2008.05.016.
20. Goral J., Kovacs E.J. In vivo ethanol exposure down-regulates TLR2-, TLR4-, and TLR9-mediated macrophage inflammatory response by limiting p38 and ERK1/2 activation. J. Immunol. 2005, 174:456-463.
21. Gravekamp C. The importance of the age factor in cancer vaccination at older age. Cancer Immunol. Immunother. 2009, 58:1969-1977. 10.1007/s00262-009-0683-x.
22. + lymphocytes by autologous tumor cells. Int. J. Cancer 1990, 46:151-152.
23. high regulatory T cells increases with age. Clin. Exp. Immunol. 2005, 140:540-546. 10.1111/j.1365-2249.2005.02798.x.
24. Grizzle W.E., et al. Age-related increase of tumor susceptibility is associated with myeloid-derived suppressor cell mediated suppression of T cell cytotoxicity in recombinant inbred BXD12 mice. Mech. Ageing Dev. 2007, 128:672-680. 10.1016/j.mad.2007.10.003.
25. Grolleau-Julius A., Abernathy L., Harning E., Yung R.L. Mechanisms of murine dendritic cell antitumor dysfunction in aging. Cancer Immunol. Immunother. 2009, 58:1935-1939. 10.1007/s00262-008-0636-9.
26. Grubeck-Loebenstein B. Changes in the aging immune system. Biologicals 1997, 25:205-208. 10.1006/biol.1997.0085.
27. Guerra N., et al. NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy. Immunity 2008, 28:571-580. 10.1016/j.immuni.2008.02.016.
28. Halabi S., et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J. Clin. Oncol. 2003, 21:1232-1237.
29. Hallett W.H., et al. Sensitization of tumor cells to NK cell-mediated killing by proteasome inhibition. J. Immunol. 2008, 180:163-170.
30. Hiratsuka S., Watanabe A., Aburatani H., Maru Y. Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis. Nat. Cell Biol. 2006, 8:1369-1375. 10.1038/ncb1507.
31. Hoover H.C., Surdyke M., Dangel R.B., Peters L.C., Hanna M.G. Delayed cutaneous hypersensitivity to autologous tumor cells in colorectal cancer patients immunized with an autologous tumor cell: Bacillus Calmette-Guerin vaccine. Cancer Res. 1984, 44:1671-1676.
32. Jeisy-Scott V., et al. Increased MDSC accumulation and Th2 biased response to influenza A virus infection in the absence of TLR7 in mice. PLoS One 2011, 6:e25242. 10.1371/journal.pone.0025242.
33. Jocham D., et al. Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial. Lancet 2004, 363:594-599. 10.1016/S0140-6736(04)15590-6.
34. Kim S.H., et al. Mage-b vaccine delivered by recombinant Listeria monocytogenes is highly effective against breast cancer metastases. Br. J. Cancer 2008, 99:741-749. 10.1038/sj.bjc.6604526.
35. Kim S.H., Castro F., Paterson Y., Gravekamp C. High efficacy of a Listeria-based vaccine against metastatic breast cancer reveals a dual mode of action. Cancer Res. 2009, 69:5860-5866. 10.1158/0008-5472.CAN-08-4855.
36. Kruit W.H., et al. Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanoma. Int. J. Cancer 2005, 117:596-604. 10.1002/ijc.21264.
37. Lechner M.G., Epstein A.L. A new mechanism for blocking myeloid-derived suppressor cells by CpG. Clin. Cancer Res. 2011, 17:1645-1648. 10.1158/1078-0432.CCR-11-0024.
38. Lustgarten J., Dominguez A.L., Thoman M. Aged mice develop protective antitumor immune responses with appropriate costimulation. J. Immunol. 2004, 173:4510-4515.
39. Maciag P.C., Radulovic S., Rothman J. The first clinical use of a live-attenuated Listeria monocytogenes vaccine: a phase I safety study of Lm-LLO-E7 in patients with advanced carcinoma of the cervix. Vaccine 2009, 27:3975-3983. 10.1016/j.vaccine.2009.04.041.
40. + human regulatory T cells in vivo: kinetics of Treg depletion and alterations in immune functions in vivo and in vitro. Int. J. Cancer 2007, 120:2723-2733. 10.1002/ijc.22617.
41. Maletto B., Ropolo A., Moron V., Pistoresi-Palencia M.C. CpG-DNA stimulates cellular and humoral immunity and promotes Th1 differentiation in aged BALB/c mice. J. Leukoc. Biol. 2002, 72:447-454.
42. Marchand M., et al. Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: a clinical report. Eur. J. Cancer 2003, 39:70-77.
43. McElhaney J.E., Meneilly G.S., Lechelt K.E., Bleackley R.C. Split-virus influenza vaccines: do they provide adequate immunity in the elderly?. J. Gerontol. 1994, 49:M37-M43.
44. Miller R.A. The aging immune system: primer and prospectus. Science 1996, 273:70-74.
45. Mocchegiani E., Malavolta M. NK and NKT cell functions in immunosenescence. Aging Cell 2004, 3:177-184. 10.1111/j.1474-9728.2004.00107.x.
46. Mocikat R., et al. Natural killer cells activated by MHC class I(low) targets prime dendritic cells to induce protective CD8 T cell responses. Immunity 2003, 19:561-569.
47. Mu L.J., et al. Immunotherapy with allotumour mRNA-transfected dendritic cells in androgen-resistant prostate cancer patients. Br. J. Cancer 2005, 93:749-756. 10.1038/sj.bjc.6602761.
48. Nakui M., et al. Potentiation of antitumor effect of NKT cell ligand, alpha-galactosylceramide by combination with IL-12 on lung metastasis of malignant melanoma cells. Clin. Exp. Metastasis 2000, 18:147-153.
49. Ogata K., et al. Natural killer cells in the late decades of human life. Clin. Immunol. Immunopathol. 1997, 84:269-275.
50. Ostrand-Rosenberg S., Sinha P. Myeloid-derived suppressor cells: linking inflammation and cancer. J. Immunol. 2009, 182:4499-4506. 10.4049/jimmunol.0802740.
51. Pardal R., Clarke M.F., Morrison S.J. Applying the principles of stem-cell biology to cancer. Nat. Rev. Cancer 2003, 3:895-902. 10.1038/nrc1232.
52. Park S.J., et al. IL-6 regulates in vivo dendritic cell differentiation through STAT3 activation. J. Immunol. 2004, 173:3844-3854.
53. Patyar S., et al. Bacteria in cancer therapy: a novel experimental strategy. J. Biomed. Sci. 2010, 17:21. 10.1186/1423-0127-17-21.
54. Phan G.Q., et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:8372-8377.
55. Plackett T.P., Boehmer E.D., Faunce D.E., Kovacs E.J. Aging and innate immune cells. J. Leukoc. Biol. 2004, 76:291-299. 10.1189/jlb.1103592.
56. Provinciali M., Argentati K., Tibaldi A. Efficacy of cancer gene therapy in aging: adenocarcinoma cells engineered to release IL-2 are rejected but do not induce tumor specific immune memory in old mice. Gene Ther. 2000, 7:624-632. 10.1038/sj.gt.3301131.
57. Provinciali M., Smorlesi A., Donnini A., Bartozzi B., Amici A. Low effectiveness of DNA vaccination against HER-2/neu in ageing. Vaccine 2003, 21:843-848.
58. at is a highly effective therapy against metastatic pancreatic cancer. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:8668-8673. 10.1073/pnas.1211287110.
59. Schlecker E., et al. Tumor-infiltrating monocytic myeloid-derived suppressor cells mediate CCR5-dependent recruitment of regulatory T cells favoring tumor growth. J. Immunol. 2012, 189:5602-5611. 10.4049/jimmunol.1201018.
60. Sharma S., Dominguez A.L., Lustgarten J. Aging affect the anti-tumor potential of dendritic cell vaccination, but it can be overcome by co-stimulation with anti-OX40 or anti-4-1BB. Exp. Gerontol. 2006, 41:78-84. 10.1016/j.exger.2005.10.002.
61. + T cells: a common basis between tumor immunity and autoimmunity. J. Immunol. 1999, 163:5211-5218.
62. Sica A., Bronte V. Altered macrophage differentiation and immune dysfunction in tumor development. J. Clin. Invest. 2007, 117:1155-1166. 10.1172/JCI31422.
63. Singh M., et al. Curcumin improves the therapeutic efficacy of Listeria(at)-Mage-b vaccine in correlation with improved T-cell responses in blood of a triple-negative breast cancer model 4T1. Cancer Med. 2013, 2:571-582. 10.1002/cam4.94.
64. Small E.J., et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J. Clin. Oncol. 2006, 24:3089-3094. 10.1200/JCO.2005.04.5252.
65. Smyth M.J., et al. Differential tumor surveillance by natural killer (NK) and NKT cells. J. Exp. Med. 2000, 191:661-668.
66. Sprecher E., et al. Effect of aging on epidermal dendritic cell populations in C57BL/6J mice. J. Invest. Dermatol. 1990, 94:247-253.
67. Tamir A., Eisenbraun M.D., Garcia G.G., Miller R.A. Age-dependent alterations in the assembly of signal transduction complexes at the site of T cell/APC interaction. J. Immunol. 2000, 165:1243-1251.
68. Tan J.T., et al. IL-7 is critical for homeostatic proliferation and survival of naive T cells. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:8732-8737. 10.1073/pnas.161126098.
69. + regulatory cells augments the generation of specific immune T cells in tumor-draining lymph nodes. J. Immunother. 2002, 25:207-217.
70. Testori A., et al. Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 Study Group. J. Clin. Oncol. 2008, 26:955-962. 10.1200/JCO.2007.11.9941.
71. Topalian S.L., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 2012, 366:2443-2454. 10.1056/NEJMoa1200690.
72. Treuting P.M., et al. Reduction of age-associated pathology in old mice by overexpression of catalase in mitochondria. J. Gerontol. A Biol. Sci. Med. Sci. 2008, 63:813-822.
73. Turner J.G., et al. Anti-CD40 antibody induces antitumor and antimetastatic effects: the role of NK cells. J. Immunol. 2001, 166:89-94.
74. + T cell subsets in human peripheral blood. Mech. Ageing Dev. 1992, 63:57-68.
75. Uyl-de Groot C.A., et al. Immunotherapy with autologous tumor cell-BCG vaccine in patients with colon cancer: a prospective study of medical and economic benefits. Vaccine 2005, 23:2379-2387. 10.1016/j.vaccine.2005.01.015.
76. Vergati M., Intrivici C., Huen N.Y., Schlom J., Tsang K.Y. Strategies for cancer vaccine development. J. Biomed. Biotechnol 2010, (in press). 10.1155/2010/596432.
77. Vermorken J.B., et al. Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial. Lancet 1999, 353:345-350. 10.1016/S0140-6736(98)07186-4.
78. Verschoor C.P., et al. Blood CD33(+)HLA-DR(-) myeloid-derived suppressor cells are increased with age and a history of cancer. J. Leukoc. Biol. 2013, 93:633-637. 10.1189/jlb.0912461.
79. Wakai Y., et al. Effective cancer targeting using an anti-tumor tissue vascular endothelium-specific monoclonal antibody (TES-23). Jpn. J. Cancer Res. 2000, 91:1319-1325.
80. Wei J., Xu H., Davies J.L., Hemmings G.P. Increase of plasma IL-6 concentration with age in healthy subjects. Life Sci. 1992, 51:1953-1956.
81. Wood C., et al. An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial. Lancet 2008, 372:145-154. 10.1016/S0140-6736(08)60697-2.
82. Yu Y.A., et al. Visualization of tumors and metastases in live animals with bacteria and vaccinia virus encoding light-emitting proteins. Nat. Biotechnol. 2004, 22:313-320. 10.1038/nbt937.